| abstract |
The present invention relates to new phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, N-oxides, pharmaceutically acceptable solvates and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them, and methods of treating allergic and inflammatory diseases, such as asthma or chronic obstructive pulmonary disease (COPD), with them. |